VLA.PA Valneva EURONEXT up 0.98% intraday ahead of Q4 16 Mar 2026: earnings to watch

Valneva SE (VLA.PA) is trading at EUR 4.55 intraday on EURONEXT, up 0.98%, as investors focus on its Q4 earnings due 18 Mar 2026. The market is watching sales mix for IXIARO and clinical progress on VLA1553 and VLA15. VLA.PA stock carries a negative EPS of -0.65 and a trailing PE of -6.99, making guidance and pipeline commentary the likely drivers of short-term moves.

Earnings calendar and preview for VLA.PA stock

Valneva reports Q4 results on 18 Mar 2026 after market close, with the company flagging revenue and clinical-readout updates. Traders should watch management comments on chikungunya candidate VLA1553 and any updated sales guidance for traveler vaccines. The scheduled release comes during intraday activity on 16 Mar 2026, increasing volatility ahead of the announcement.

Q4 drivers: pipeline, sales and guidance for VLA.PA stock

Core commercial sales (IXIARO, DUKORAL) and milestone or regulatory updates for VLA1553 and VLA15 will determine tone. A stronger-than-expected chikungunya approval path or higher IXIARO volume could lift revenue. Conversely, slower uptake or weaker gross margins would pressure the stock. Expect questions on cash runway given research spend at 47.41% of revenue and free cash flow negative metrics.

Valuation and key metrics for VLA.PA stock

Valneva’s market cap is EUR 781.97M with 172,088,678 shares outstanding. Key ratios: EPS -0.65, PE -6.99, price/sales 4.35, price/book 4.90, debt/equity 1.30, current ratio 1.78. Recent growth: revenue increased 10.32% in FY 2024. These metrics show biotech valuation premium versus Healthcare sector average PE 29.24 and PB 2.55, reflecting pipeline value but persistent profitability risks.

Technicals, liquidity and trading context for VLA.PA stock

Intraday range is EUR 4.48–4.64 with volume 337,265 versus average 1,029,996. Momentum indicators: RSI 49.19 and MACD histogram slightly negative. Price sits above the 50-day average EUR 4.35 and 200-day EUR 3.83, signaling medium-term support. Low relative volume suggests a muted move until the earnings print triggers higher participation.

Meyka AI grade and forecast for VLA.PA stock

Meyka AI rates VLA.PA with a score out of 100: 61.71 (Grade B, SUGGESTION: HOLD). Meyka AI, an AI-powered market analysis platform, derives this grade from S&P 500 comparison, sector and industry benchmarks, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a yearly price of EUR 5.30, implying an upside of 16.48% versus the current EUR 4.55. Forecasts are model-based projections and not guarantees.

Earnings risk and analyst scenarios for VLA.PA stock

Scenario planning: conservative downside target EUR 3.50 if guidance disappoints or trials slow; base case EUR 5.30 aligned with Meyka forecast; bullish EUR 6.50 if chikungunya approval and post-launch contracts accelerate revenue. Short-term risks include cash burn, clinical set-backs and limited liquidity compared with peers. Catalysts: regulatory milestones, partner deals and clearer 2026 guidance.

Final Thoughts

VLA.PA stock sits at a crossroads ahead of Q4 results on 18 Mar 2026. At EUR 4.55 intraday, the market is pricing recovery versus a recent low of EUR 2.25 in the last 12 months but remains below the year high EUR 5.42. Valneva shows pipeline upside and commercial revenue levers, tempered by negative EPS (-0.65), elevated debt/equity (1.30) and negative free cash flow. Meyka AI’s forecast model projects EUR 5.30 for the year, an implied upside of 16.48%. That projection informs our base-case price target but comes with clear caveats: forecasts are model-based and not guarantees. Traders should size positions carefully, watch guidance on vaccine rollouts and regulatory paths, and track post-earnings liquidity as average volume is roughly 1,029,996 versus current 337,265. For an up-to-date quote and live alerts see our Valneva page on Meyka and the linked earnings coverage below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.